GlassScriptPhysician profile
Michelle Renee Carpenter
NPI 1952312241
$4,756.35
in general payments reported to CMS, 2019-2025
31 companies · $891 in 2025
The $891 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $403 · 2021: $631 · 2022: $311 · 2023: $922 · 2024: $1,176 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,964.44 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,607.39 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.16 | 2019-2025 | Jardiance |
| Amgen INC. | $398.61 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $396.02 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $278.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Supernus Pharmaceuticals, INC. | $185.40 | 2019-2022 | |
| Astellas Pharma US INC | $158.76 | 2019-2023 | Myrbetriq |
| Glaxosmithkline, LLC. | $148.52 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $146.05 | 2025 | |
| Pfizer INC. | $143.26 | 2020-2025 | |
| Merz North America, INC. | $141.51 | 2025 | |
| Madrigal Pharmaceuticals | $113.73 | 2024 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $68.87 | 2019-2020 | |
| Boston Scientific Corporation | $68.02 | 2025 | Cds - Mct/Cem Monitoring, Bodyguardian |
| Genentech USA, INC. | $65.82 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $55.26 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $35.58 | 2019 | |
| Insulet Corporation | $28.25 | 2023 | Omnipod |
| Allergan, INC. | $26.15 | 2020 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $23.93 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $23.59 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $20.21 | 2020 | |
| Ardelyx, INC. | $19.02 | 2025 | Ibsrela |
| Radius Health, INC. | $16.13 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.08 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.52 | 2019 | |
| Echosens North America, INC. | $13.24 | 2024 | Fibroscan |
| Novartis Pharmaceuticals Corporation | $12.80 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.79 | 2023 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.